Severe and steroid-resistant Crohn's disease

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Management strategies for moderate-to-severe disease differ from steroid-refractory or dependent conditions.
• Steroid-refractory/dependent patients often present with less acute disease presentations.

Purpose of the Study:

• To outline current therapeutic approaches for different patient groups.
• To identify effective treatments for achieving steroid-free remission.

Main Methods:

• Review of existing literature on treatment modalities.
• Comparison of efficacy for various systemic and surgical interventions.

Main Results:

• Systemic corticosteroids are first-line for moderate-to-severe disease.
• Anti-TNF agents are alternatives for steroid non-responders or contraindications.
• Purine analogues, methotrexate, and infliximab demonstrate efficacy in steroid-refractory/dependent disease.
• Natalizumab shows potential for patients refractory to anti-TNF agents.

Conclusions:

• Treatment selection depends on disease severity and response to corticosteroids.
• A range of immunosuppressors and surgical options exist for refractory cases.
• Achieving steroid-free remission is a key goal in managing steroid-dependent/refractory disease.